Covid-19 roundup: J&J be­gins piv­otal Phase III tri­al for vac­cine; Con­tro­ver­sial hu­man chal­lenge tri­als to be­gin in Lon­don — re­port

John­son & John­son an­nounced it’s be­gin­ning a piv­otal Phase III tri­al for its Covid-19 can­di­date, JNJ-78436735 — the first sin­gle-dose vac­cine in this stage. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA